Search research articles
Contact Us
Filters
Showing results (421-430 of 509) with videos related to
Page
of 51
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
George D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Cancers
|
January 21, 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network
Clémence Romeo, Olivia Le Saux, Margaux Jacobs, et al.
Gynecologic Oncology
|
October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
S Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
Cancers
|
August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini, Stanislas Quesada, Pierre Meeus, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
Gynecologic Oncology
|
May 12, 2026
Endometriosis and ovarian cancer risk
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
May 21, 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Page
of 51
Search research articles
Search
Showing results (421-430 of 509) with videos related to
Sort By:
Page
of 51
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
George D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Cancers
|
January 21, 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network
Clémence Romeo, Olivia Le Saux, Margaux Jacobs, et al.
Gynecologic Oncology
|
October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
S Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
Cancers
|
August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini, Stanislas Quesada, Pierre Meeus, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
Gynecologic Oncology
|
May 12, 2026
Endometriosis and ovarian cancer risk
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
May 21, 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Page
of 51